CD81+ erythroblasts expand during AML and interact with malignant cells to activate the MIF/CD74-mTORC1-Egln3 axis, ultimately driving disease progression by reshaping leukemic cell metabolism. This evidence concerns the gene EGLN3 and acute myeloid leukemia.